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Background: Reinfections of Chlamydia trachomatis (Ct) are common. In a two-armed intervention study at an
urban STI clinic in the Netherlands, heterosexual Ct-positive visitors received an invitation for retesting after
4–5 months. Interventions were either home-based sampling by mailed test-kit, or clinic-based testing without
appointment.
Methods: Data collection included socio-demographic and sexual behavioural variables at first (T0) and repeat test
(T1). Participation in retesting, prevalence and determinants of repeat infection among study participants are
described and compared with findings from non-participants.
Results: Of the 216 visitors enrolled in the study, 75 accepted retesting (35%). The retest participation was 46%
(50/109) in the home group versus 23% (25/107) in the clinic group (p = 0.001). Men were less often retested than
women (15% versus 43%, p < 0.001). The overall chlamydia positivity rate at retest was 17.3% (13/75) compared to
12.4% seen at all visits at the STI clinic in 2011. Repeated infections were more frequent among non-Dutch than Dutch
participants (27.0% versus 7.9%; p = 0.04) and in persons reporting symptoms (31.0% versus 7.0%; p = 0.01). Both
untreated infections of current partners as well as unprotected sex with new partners contribute to repeated infections.
Conclusion: The high rate of repeated infections indicates the need for interventions to increase retesting;
improvement of partner-management and risk reduction counselling remain necessary. Home- based testing was
more effective than clinic-based testing. However other strategies, including self-triage of patients, may also increase
repeat testing rates and personal preferences should be taken into account.
Keywords: Chlamydia trachomatis, Screening, Repeated infection, Retest rate, Chlamydia positivity, Intervention
retesting, Home-based testing versus clinic testingBackground
Repeat infections of Chlamydia trachomatis are frequent
and challenging to control [1-4]. Repeat infections increase
the probability to develop PID and other complications.
Recently, in a population based systematic screening project
in Amsterdam, Rotterdam and South- Limburg, infected
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reproduction in any medium, provided the orafter 6 months, based on the advice of a previous pilot-
screening project [5]. Sixty-six percent accepted retesting
and the proportion with repeat infections was twice the
chlamydia positivity at first test [6]. In this Chlamydia
Screening Implementation programme (CSI), invitations
were sent by postal service and further communication was
via the internet; participants received test-packages at
home, both for initial tests and retests. In Rotterdam,
baseline chlamydia positivity (5.1%) and repeat infection
rates (11.3%) were higher than in the other regions [6].
National guidelines in the Netherlands recommend
annual rescreening of Chlamydia trachomatis infectedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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retesting of positives and the way to achieve retesting in
routine care. Along with STI care in general practice
(GP), people at high risk for STI have access to free testing
at STI clinics of public health services [8]. The repeat
infection rate at STI clinics is not included in the Dutch
national surveillance programme, although a recent study
in 2012 showed a 19% repeat infection rate in an STI
clinic in South Limburg [9]. Repeat testing is a timely
way to detect re-infections (resulting from incomplete
treatment of index or partner or unprotected sex between
the same partners before infection clearance). It can
improve the detection of repeated, newly acquired
infections in a group with a proven high-risk profile
for chlamydia. However, uptake of repeat testing is
generally low and the most effective way to increase
the uptake is unknown. Guy et al. performed a systematic
review and identified posting testkits as an important
strategy to increase repeat testing uptake [10].
Our aim was to compare participation and chlamydia
positivity at retest using two different recall methods: (1)
offering home-based test-kits versus (2) sending personal
invitations for retesting at the clinic. We aimed to assess
demographic and behavioural factors determining par-
ticipation in retesting as well as determinants for repeat
infection and compare these to available data on routine
care at the STI clinic.
Methods
Study population
Our prospective Chlamydia Retest Implementation (CRI)
study was carried out in heterosexual men and women at
an STI clinic with a genital Chlamydia trachomatis
infection, with whom the risk of re-infections was
discussed at the treatment consultation. Patients were
asked for consent to participate in a study to facilitate
retesting, emphasizing that participants would have
personal health gain. We excluded patients with PID,
pregnant women, patients with allergies to or other
contra-indications for the first choice treatment
(Azithromycine), clients under 16 years, and men who
have sex with men, because for the latter group the advice
is bi-annual screening for all STI. Furthermore, patients
with clinically evident signs of infection who receive
antibiotic treatment for chlamydia at first visit, i.e. men
with symptomatic urethritis or with leucocyturia, and
patients notified by a current sexual partner were also
excluded, because they did not come back for consultation
when the diagnosis was confirmed.
Study procedures
Two recall methods for retesting were compared: (1) the
‘clinic group’ was asked to visit the STI clinic for
retesting without appointment and were given a personaltestkit at waiting at the counter (i.e. an envelope prepared
for them with sampling tube for urine collection for men
or vaginal swab for women); (2) the ‘home group’ were
sent a similar testkit to their home address (or other
address of choice), which could be sent back free of
charge to the laboratory directly. Testing for Chlamydia
trachomatis was carried out by NAAT (BD VIPER SDA,
Becton-Dickinson, New Jersey).
Patients who had given written consent for the CRI
study at baseline (participants) were entered in a
database and CRI participants completed a web-based
questionnaire at the clinic and provided an email address.
Computerized randomisation into home group (home-
based testing) or clinic group (STI clinic-based testing)
was done using an anonymous list of ID numbers and sex
of participants. Enrolled patients were invited for repeat
testing 4–5 months after treatment at T0. Using a list of
participants, the research nurse sent invitations by email
at T1 with information about the retesting method and a
second questionnaire. People who did not respond to the
initial invitation received a reminder email within 7 days.
A reminder was also e-mailed to persons in the home
group whose samples were not received within 2 weeks.
Responders received their result by SMS and were invited
for treatment at the clinic if positive. In case the reminders
did not result in retesting after 4 weeks, a questionnaire
on reasons for non-response was e-mailed. For an
overview see flowchart (Figure 1). The Medical Ethical
Committee of the Erasmus University of Rotterdam
approved of the study.
Sample size calculation
The sample size was determined by the number of
people positive for chlamydia and the proportion
consenting to participate. Anticipating 100 positives per
month (average first 6 months 2011), and an initial
participation/consent rate of 70%, we expected to be
able to recruit 280 participants in a study period of
4 months. This would provide the two groups of 124
persons needed to compare the response rate between
the two interventions with 90% power (β) and 5%
error (α). We expected a retest rate of about 70% for
the home sampling group (based on 66% in the recent
CSI screening programme with home-based retest) and
50% in the clinic group [6].
Study period
The inclusion period for the retest implementation study
was 15 March – 15 August 2011. Invitations for
retesting were sent between 15 August to 15 November.
The time of the first consultation was marked as ‘T0’,
the time of retest as ‘T1’. Initially, invitations were sent
4–5 months after the first positive test, but to include
more patients, invitation for retesting was done earlier
Figure 1 Flow chart of patient enrolment and follow-up of the Chlamydia Repeat test Implementation study and results on
participation and positivity.
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retest was defined as a test performed 42–245 days after
the first chlamydia test in the study period. Retesting within
42 days after treatment was considered a test of cure.
Data collection and statistical methods
The database was built using a combination of variables
routinely collected at the clinic and additional information
collected for the study about the timing of procedures as
well as data collected in questionnaires. Data collection in
the questionnaire at T0 included socio-demographic
variables, such as age, gender and ethnicity (based on
country of birth of invitee and of parents), as well asother background and behavioural variables (education
level, history of chlamydia infection, (self-reported) STI
related complaints, number of sexual partners in the previ-
ous 6 months). Reasons for non-participation at baseline, if
given, were registered during the consultation by the
nurses. At T1 we assessed whether the person had had any
STI related self-reported symptoms/complaints since the
first test, the number of (new or previous) sexual partners
in the 6 months before T1 and whether his/her partner had
been treated at T0.
A variable sexual risk was constructed for participants
of the CRI study: a person was assumed to have been
at risk for STI when he/she had sex with untreated
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baseline or when he/she acquired a new sexual partner after
treatment of baseline infection. Retest rate was calculated
by counting the number of persons testing again within a
period of 42–245 days after first testing, per home-test and
clinic-test sub-group. We also checked if participants came
back to the clinic for a chlamydia test within the follow-up
period without making use of the retest offer. Chlamydia
positivity was defined as the number of positive tests
divided by all tests performed.
Univariate and multivariate logistic regression analyses
were conducted to assess associations between participation
at repeat testing after 6 months (dependent variable) and
socio-demographic and self-reported behavioural variables
(independent variables) as well as the correlates of
chlamydia positivity. Backward stepwise logistic regression
analyses were performed, including all variables for
retest rate, and for positivity variables with a p-value
for the likelihood ratio test of < 0.2. Results are given as
odds ratios (ORs) with 95% confidence intervals (CIs).
Adjusted ORs give estimated effects of each variable
after adjustment for all other variables.
Results
In the inclusion period for the study, 453 Chlamydia
trachomatis infections were diagnosed among heterosexual
clients of the STI clinic. Of this group, 282 persons were
invited to participate, while 112 persons were excluded
because they received treatment at their first visit. For 59
chlamydia-positive patients the clinic staff forgot to ask.
Participation CRI and retest rate
At baseline, 216 individuals consented to participate in
the study and filled in the first questionnaire (participants
at T0) and 66 refused to participate (77% acceptance).
Participants were invited for retesting by email 93–
174 days (median 138) after their first consultation.
Fifty-five percent 63% (119/216) filled in the questionnaire
at T1 and 75 of them were tested. Overall retest rate was
35% (75/216). Retest rate was significantly higher in the
home group (46%, 50/109) than in the clinic group
(23%, 25/107, p < 0.001) (See Figure 1 and Table 1).
Men were less often retested than women (15% versus
43%, p < 0.001; Table 1). Other demographic variables such
as age, ethnicity, and educational level did not determine
repeat testing rate. Retest rate was associated with sexual
behavioural risk factors at T0: retest rates were lower in
individuals with three or more partners in the 6 months
before testing at T0 (24%) compared to those with one
partner (38%; p = 0.07). The presence of self-reported
STI-related symptoms at T0 did not influence repeat
test rate. Retest rate was not associated with behavioural
risk during the period since treatment: the number of
sexual partners or sexual contact with a new partnerin the 6 months after treatment did not influence retest
rate. There was no effect on retest rate of (self-reported)
symptoms since treatment at baseline, neither in men nor
in women (Table 1). In multivariate analysis, including
determinants available at T0 and T1, only the method of
recall (home group versus clinic group) and gender were
independent determinants for retesting (Table 1).
The interval for retest invitation varied from 3–5 months.
There was no difference in response rate by the duration of
the period between the initial diagnosis and the retest invi-
tation (21% for 3–4 months duration; 37% for 4–5 months
and 40% for 5–6 months (p = 0.14)).
Repeat infections
We found 13 repeat infections at T1. Three of these
13 infected persons had already had a Chlamydia
trachomatis infection before the infection at baseline.
One person reported an infection since treatment of
the infection at T0 but tested negative at T1. The
overall chlamydia positivity rate was 17.3% (13/75)
and there was no significant difference between home
and clinic group (16.0% versus 20.0% p = 0.4). Chlamydia
positivity in women was 18.5% (12/65) and 10.0% (1/10)
in men (p = 0.52, see Table 2). We did not find a
significant difference in chlamydia positivity between
age-groups, however 10 out of 13 infections were in
people in the age-group under 25 years. Also educational
level was not significantly related with chlamydia
positivity. Repeat infections were found more frequently
among non-Dutch than among Dutch respondents
(27.0% [10/37] versus 7.9% [3/38]; p = 0.04). Persons
reporting symptoms in the period since treatment had
a significantly higher risk of infection than those without
(31.0% [9/29] versus 7.0% [3/43]; p = 0.007).
Although we did not find significant differences
(due to the small number of infections), the risk of
reinfection seemed to depend on partner treatment at
baseline (T0) and sexual contacts reported at T0 and
between T0 and T1. Persons with a new sex partner
since treatment had a higher repeat-infection rate
(23.7% [9/38]) than persons without a new partner
(8.8% [3/34]; p = 0.10), and rates increased with the
number of reported partners in the 6 months before
retesting: 9.4% for one; 21.1% for two and 27.8% for
three or more partners (ns).
The rate of repeat infection was lower among those
who had sex with a previous partner who was treated
at baseline (7.7% [2/26]) than those with an untreated
partner (17.4% [4/23]). Although the variable sexual
risk could not be calculated for all tested persons, it
shows that persons who only had sex with a new
partner were at the highest risk for repeat infections
(31.3% [5/16]), followed by those having sex with
both new and old partners (28.6% [2/7]).
Table 1 Retest rates per group and determinants of repeat testing, CRI study Rotterdam 2012
Univariate logistic regression Multivariate (n = 216)
N invited n tested % tested OR 95% CI p OR 95% CI p
Type of test offered (n = 216)
Test-kit by post 109 50 45.9 2.8 (1.5-5.0) 0.001 2.9 (1.6-5.4) <0.01
Invitation to STI clinic 107 25 23.4 1
Gender (n = 216)
Male 65 10 15.4 1
Female 151 65 43.0 4.2 (2.0-8.8) <0.001 4.3 (2.0-9.4) <0.001
Age (n = 216)
15-19 years 47 15 31.9 1.0 (0.5-2.3) 0.94 ns
20-24 years 105 40 38.1 1.4 (0.7-2.6) 0.37
25 years and above 64 20 31.3 1
Ethnicity (n = 216)
Dutch 99 38 38.4 1 0.30 ns
non-Dutch 117 37 31.6 0.7 (0.4-1.3)
Educational level (n = 216)
Low 58 16 27.6 0.8 (0.4-1.8) 0.62 ns
Medium 82 35 42.7 1.6 (0.8-3.1) 0.15
High 76 24 31.6 1
CT infection previously to infection at T0 (n = 216)
Yes 61 26 42.6 1.6 (0.9-3.0) 0.13
No 155 49 31.6 1 ns
Complaints reported at T1 (n = 119)
Yes 47 29 61.7 1.09 (0.5-2.3) 0.83
No 72 43 59.7 1
No of partners in past 6 months at T0 (n = 215)
0 partners 6 3 50.0 1.7 (0.3-8.9) 0.55 ns
1 partner 72 27 37.5 1
2 partners 57 26 45.6 1.4 (0.7-2.8) 0.35
3 or more partners 80 19 23.8 0.5 (0.3-1.0) 0.07
No of partners in past 6 months at T1 (n =119)
0 partners 7 3 42.9 0.5 (0.1-2.3) 0.35 ns
1 partner 52 32 61.5 1
2 partners 29 19 65.5 1.2 (0.5-3.1) 0.72
3 or more partners 31 18 58.1 0.9 (0.4-2.1) 0.75
Sex with old not treated partner(s) (n = 118) T1
No 42 26 61.9 1 ns
Yes 41 23 56.1 0.8 (0.3-1.9) 0.59
Not relevant, no sex with old partner 35 23 65.7 1.2 (0.5-3.0) 0.73
New sex partner since treatment (n = 119) T1
Yes 60 38 63.3 1.2 (0.6-2.5) 0.68 ns
No 59 34 57.6 1
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Table 1 Retest rates per group and determinants of repeat testing, CRI study Rotterdam 2012 (Continued)
Sexual Risk (n = 113) T1
No old or new partners 50 31 62.0 1 ns
Risk through old partners only 25 16 64.0 1.1 (0.4-3.0) 0.87
Risk through new partners only 24 16 66.7 1.2 (0.4-3.4) 0.70
Risk through new as well as old partners 14 7 50.0 0.6 (0.2-2.0) 0.42
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Among the 66 persons who did not consent to par-
ticipate in the study at T0, the following reasons for
non-participation were reported by the nurse: 11
intended to move away, 9 did not have time, 9 did
not consider the retest necessary thought not to
have a reason for retesting, 8 did not want to have a
testkit sent home, 6 wanted to make an appointment
for testing themselves, 2 stated not to have email, 10 had
other reasons and for 11 the reason was unknown.
The non-response questionnaire at T1 was sent to
all CRI-participants who did not make use of the
retest offered within the study. In a few persons, testing
overlapped with receiving the non-response questionnaire
and they were excluded from analysis. Twenty percent of
non-responders (28/141) answered the questionnaire.
Fourteen persons gave lack of time as a reason for
not testing, three had already been tested again since
the previous treatment, two did not have a new sex
partner, and nine had other reasons. When asked
about their opinion on the testing recall method, the
non-responders in the clinic group (n = 24) mentioned
lack of time (n = 9), preference to receive a testkit at
home (n = 9), that they had forgotten (n = 5) or other
reasons (n = 5) while the non-responders in the home
group (n = 4) mentioned various non-specific reasons
for not using the test kit.
Among 141 non-respondents who initially consented
to participate in the retest study, 26 (18%) tested out of
own initiative in our clinic: 22% (18/82) from the clinic
group and 14% (8/59) from the home group. Six among
these 26 (23%) were chlamydia positive.Discussion
In this prospective trial we compared two methods of
recall for retesting of chlamydia infected heterosexual
visitors of a Dutch STI clinic. We found 17.3%
repeated infections, which is higher than the 12.4%
baseline Chlamydia trachomatis infections. The over-
all retest rate was 35%; a higher retest rate was
achieved by active recall for home-based repeat test-
ing (46%) than recall for repeat testing at the STI
clinic (23%). Females were more likely to participate
in the retest.Strengths and limitations
To our knowledge, this is the first European prospective
study investigating the effect of systematic recall on
retesting and positivity rates at an STI clinic comparing
home-based versus clinic-based testing. Several recall
studies only report retesting rates and not positivity
rates [11,12]. A disparity between the home-based and
clinic-based test group was that we sent an additional
reminder to those who had received a testkit at home
and did not use it, thereby introducing a bias favouring
participation in the home-based test group. Excluding the
eight persons who responded after having received the
reminder, the participation rate was 35%, which is still
higher than the clinic-based group (23%; p = 0.016).
Our study was seriously limited by the time-frame
within which it had to be carried out, which made it
necessary to send part of the retest invitations earlier
than 4 months after first treatment. This impaired the
comparability to other studies and may have affected the
assessment of determinants for repeat infection. We did
not however find a significant difference in response rate
by the duration of the period between the initial diagnosis
and the retest invitation and our retest interval is still in
line with a recent modelling study that showed that
people were at a high risk of becoming repeatedly
infected 2–5 months after treatment [13].
Our findings are also limited by the exclusion of patients
who were treated at first consultation because of urethritis
or because they were notified by their partner. Including
them in the study seemed not to be feasible, but the
proportion of chlamydia cases treated at first consultation
was higher than expected beforehand. Therefore the effect
of the presence of complaints at T0 on retesting within the
study population is limited to persons with self-reported
complaints like vaginal discharge, itching, dysuria without
leucocyturia and might therefore be lower than in reality.
Another limitation of our trial was that we did not have a
randomised control group with standard care only. Conse-
quently we do not know whether doing an intervention is
more effective than only mentioning retesting, nor do we
know whether by any of our interventions we detected
more infections than without intervention. We assessed the
retest rate in non participants to explore this. During our
study period, the proportion of Chlamydia trachomatis
Table 2 Positivity rates and determinants for Chlamydia trachomatis repeat infections, CRI study Rotterdam 2012
Univariate logistic regression Multivariate (n = 72)
N Tested n pos % pos OR 95% CI p OR 95% CI p
Type of test offered (n = 75)
Test-kit by post 50 8 16.0 0.8 (0.2-2.6) 0.67
Invitation to STI clinic 25 5 20.0 1
Gender (n = 75)
Male 10 1 10.0 1 ns
Female 65 12 18.5 2.0 (0.2-17.7) 0.52
Age (n = 75)
15-19 years 15 4 26.7 2.1 (0.4-11.0) 0.40
20-24 years 40 6 15.0 1.0 (0.2-4.5) 1.0
25 years and above 20 3 15.0 1
Ethnicity (n = 75)
Dutch 38 3 7.9 1 ns
Non-Dutch 37 10 27.0 4.3 (10.8-17.3) 0.04
Educational level (n = 75)
Low 16 3 18.8 5.3 (0.5-56.4) 0.17 ns
Medium 35 9 25.7 8.0 (0.9-67.7) 0.06
High 24 1 4.2 1
Age at first sex (n = 75)
< 16 years 37 5 13.5 0.9 (0.1-5.1) 0.87
16-17 years 25 6 24.0 1.7 (0.3-10.1) 0.54
18 years and above 13 2 15.4 1
CT infection previously to infection at T0 (n = 75)
Yes 26 3 11.5 0.5 (0.1-2.0) 0.34
No 49 10 20.4 1
Complaints reported at T1 (n = 72)*
Complaints yes 29 9 31.0 6.0 (1.5-24.6) 0.01 1.61 (1.6-51.2) 0.01
Complaints no 43 3 7.0 1 1
No of partners in past 6 months at T1 (n = 72)*
0 partners 3 0 0.0 0 (0.0-0.0) 0.99 ns
1 partner 32 3 9.4 1
2 partners 19 4 21.1 2.6 (0.5-13.0) 0.25
3 or more partners 18 5 27.8 3.7 (0.8-17.9) 0.10
Ethnicity sex partner T1 (n = 54)
Concordant (NL/NL) 20 3 15.0 1
Discordant (NL/non-NL) 14 2 14.3 0.9 (0.1-6.5) 0.95
Concordant (non-NL/non-NL) 20 6 30.0 2.4 (0.5-11.5) 0.26
Sex with previous - untreated - partner; T1 (n = 72)*
No 26 2 7.7 1 ns
Yes 23 4 17.4 2.5 (0.4-15.3) 0.31
Not relevant, no sex with previous partner 23 6 26.1 4.2 (0.8-23.6) 0.10
New sex partner since treatment T1 (n = 72)*
Yes 38 9 23.7 3.2 (0.8-13.0) 0.10 ns
No 34 3 8.8 1
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Table 2 Positivity rates and determinants for Chlamydia trachomatis repeat infections, CRI study Rotterdam 2012
(Continued)
Sexual Risk (n = 70)*
No old or new partners 31 1 3.2 1 ns
Risk through old partners only 16 2 12.5 4.3 (0.4-15.3) 0.25
Risk through new partners only 16 5 31.3 13.6 (1.5-130.1) 0.02
Risk through new as well as old partners 7 2 28.6 12.0 (0.9-158.4) 0.06
* Denominators of parameters are less than 75, due to the fact that not all respondents answered these questions.
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but did return for a retest at the STI clinic on their own
initiative within 42–245 days was 19% (45/237): 15%
(17/112) in the group treated at first consultation 12%
(8/66) in the subgroup refusing to take part in the study at
T0 and 34% (20/59) in the subgroup in which the clinic
staff forgot to ask for consent to participate in the study.
The positivity rate in those 45 persons was 22% (10/45).
Although there may have been a bias because it was not a
randomized control group, our findings suggest that the
retest rate with active recall is higher than without recall
(35% versus 19%), while the positivity in the recall group
may be somewhat lower (17% versus 22%), probably due
to ‘self-triage’ as a result of new sexual risk or presence of
STI-related complaints.Comparison with other studies
Our results are in line with a recent retrospective study
based on laboratory data from the Netherlands which
found similarly high positivity rates after 3–12 months
among patients in the STI clinic (19.4%), at gynaecologists
(14.8%) or GPs (17.4%) [9]. The determinants for reinfec-
tions we found are known risk factors for Chlamydia
trachomatis infections: young age, non-Dutch ethnicity,
low education [3-6,14,15].
We do not know if persons are commonly retested at
the GP, although we expect it may be a barrier that they
have to pay for STI-tests at the GP within their own-risk
payment in health care insurance whereas in the Dutch
STI clinics STI-tests are provided for free. In the recent
retrospective Dutch study, rescreening rates were similar
for the STI clinic (33.4%) and gynaecologists (30.3%) but
lower for general practitioners (23.0%) [9]. As no practical
guidelines on retesting are in place in the Netherlands,
retests are likely to be only offered to a group of higher-risk
cases selected by provider triage or self-triage, as the
authors suggest.
Our results are based on a high-risk STI clinic population
in a large, multi-ethnic city. Retest rate as well as positivity
may well differ in other areas or populations. The retest
rate in our study was lower than in a previous Chlamydia
Screening Implementation (CSI) study [6] which achieved aretest rate of 66% . A difference with the CSI study is that
the participants in were already used to home-testing and
had chosen, by participating, to receive a testkit at home
and receive related information via the internet; in addition,
two automatic reminders were sent to non-responders in
CSI versus one in our study and CSI made use of an official
website with specific information. The participants in our
study had no previous experience with home-based testing
and may have been in favour of coming to the clinic,
although the test rate among those who could come
to the clinic at a convenient time was relatively low.
Retest rates of 21-27% were achieved in other studies
with mailed home-test kits when retesting was done after
3 months or more [16,17]. Often higher retest rates
(up to 48%) are reported in the period <3 months,
tests which may be tests of cure [17].Interpretation
Despite the limitations, we could show that - as expected -
repeated infections are a common problem in chlamydia
patients. STI clinics should provide retesting advice and
offer retesting in a more proactive way to Chlamydia
trachomatis infected individuals.
To achieve higher retest rates, combined strategies
may be required. Among patients using mailed test kits
and telephone reminders in the US, the re-screening
rates were 59.2% at family planning clinics and 43.5% at
STI clinics [17]. In a meta-analysis, it was found that
mailing testkits is an effective strategy to increase
rescreening, but also that telephone reminders are
promising. Text messaging (SMS) has been found to
have similar effects as letters and phone calls, but is
much cheaper and easier to implement [10].
Although the home-based testkit achieved the highest
participation rate in our study, the majority of kits was not
used and the question remains whether this method is
cost-effective. Sending invitations, testkits and reminders
manually is time-consuming and is possibly not achievable,
logistically or financially, in STI clinic settings. Even without
home-based testkits, we found that patients frequently
came for a retest, also on their own initiative. Offering a
retest and reminders by SMS may be more feasible.
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http://www.biomedcentral.com/1471-2334/13/239Recently, two studies in Australia demonstrated a
moderate increase in repeat testing by sending a short
message reminder, although combining SMS-text-messages
with a financial incentive did not have further impact [12].
This impact may be influenced by the reason for testing
and type of relationship of patients. In MSM who are more
familiar with repeat STIs testing, reminders by SMS have
been shown to double the repeat test rate [18]. Challenges
in using SMS reminders are dealing with undeliverable
messages and ensuring that health professionals actually
send them to the selected patients [11,12]. Automated SMS
reminders should preferably be built-in to electronic patient
registration systems. It has been demonstrated in various
interventions that patients may choose different strategies
depending on their personal circumstances [10], hence per-
sonal preferences should be taken into account. However,
providing good and accessible retest services is not the only
way to reach a higher retest rate. Effective sexual health
education that seeks to change attitudes to testing and risk
perception among young people at risk for chlamydia is
crucial. The accessibility of health services, low-risk percep-
tion, fear and worry were described as barriers to testing in
an European review on HIV testing [19]. Accessibility of
health services and sufficient self- efficacy are important
but not sufficient explanations [20], as self-efficacy
was not a significant predictor of STI testing among
adolescents [21,22] but attitudes and susceptibility were.
Conclusions
High rates of Chlamydia trachomatis repeat infections
indicate the need for an active offer and support of
retesting and should be included in guidelines and rec-
ommendations for STI control.
Home-based testing was more effective than clinic-
based testing. However, various strategies including self-
triage of patients may increase repeat testing and personal
preferences should be taken into account. Automated
SMS reminders inviting patients for retesting at the clinic
may be the most cost effective and feasible method of
choice to be implemented by STI clinics. A prerequisite
for strategies for retesting, like any good public health
intervention, is that they are proven to be (cost)effective
and can be paid for within the public health care system.
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